Longeveron Promotes Marie Washburn to CFO Amid Critical Clinical Trial
Event summary
- Marie Washburn promoted to CFO of Longeveron, effective July 13, 2026.
- Washburn succeeds Lisa Locklear, who is stepping down for board opportunities.
- Longeveron anticipates Phase 2b clinical trial results for HLHS treatment in Q3 2026.
- Washburn brings over 20 years of experience in pharmaceutical and biotech sectors.
The big picture
Longeveron's promotion of Marie Washburn to CFO underscores a strategic focus on financial stability amid critical clinical milestones. The company's Phase 2b trial results for HLHS, expected in Q3 2026, could significantly alter its trajectory in the regenerative medicine space. Washburn's extensive experience in biotech finance positions her to manage operational and financial challenges during this pivotal period.
What we're watching
- Clinical Trial Outcomes
- How the Phase 2b trial results for HLHS will impact Longeveron's strategic direction and investor confidence.
- Financial Strategy
- Whether Washburn can navigate Longeveron through potential capital-efficient transitions amid critical trial phases.
- Regulatory Pathway
- The pace at which Longeveron can secure FDA alignment and approval for its stem cell therapy indications.
Related topics